The TroFuse-005 trial involved 776 patients with endometrial cancer whose disease worsened after receiving both platinum ...

TMT, a new cancer drug, demonstrated strong results in phase 3 trials for advanced or recurrent endometrial cancer patients.

The TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) demonstrated a statistically significant ...

She was the most outgoing caring person in the world in September 2020. At the age of 63 Sherlyn Webb was diagnosed with uterine cancer but was told the disease had been caught early. We thought that ...

Learn more Merck MRK announced that the pivotal phase III TroFuse-005 study, which evaluated its pipeline candidate, ...

Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug ...

Sheryl Crow shared that she experienced one of the most difficult periods in her life when she was diagnosed with breast ...

The TROP2-directed antibody-drug conjugate demonstrated superior efficacy over physician’s choice of chemotherapy in patients previously treated with platinum-based therapy and immunotherapy.

Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial ...

Sheryl Crow shared that she experienced one of the most difficult periods in her life when she was diagnosed with breast ...

The Minns Labor Government is delivering over $11 million in funding to support novel cancer research projects, including research into incurable ...